Paclitaxel/Ifosfamide/Cisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor
Status:
Recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
Germ cell tumor has generally good prognosis, but high risk germ cell tumor has still very
poor prognosis. There remains the need of further improvement with other chemotherapy
strategy. Especially more than 11 years old, mediastinal germ cell tumor, stage 3 or 4
extragonodal germ cell tumor or the remained tumor after the primary treatment are the group
with the poorest prognosis.
Paclitaxel is widely used chemotherapeutic agent in adults and the experience of the agent
has also been accumulated in children. The paclitaxel, ifosfamide, cisplatin (TIP) regimen
has been used 2nd-line treatment for germ cell tumor and there is some promising result of
the role of TIP in first line germ cell tumor treatment. In high risk pediatric germ cell
tumor patients, TIP regimen will be able to reduce lung toxicity from the bleomycin as the
standard regimen and to improve the survival. In this trial, the efficacy and safety of TIP
as the first line treatment for germ cell tumor will be elucidated.